Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 19 | 2025 | 449 | 4.200 |
Why?
|
| Ionic Liquids | 4 | 2025 | 20 | 2.730 |
Why?
|
| Drug Carriers | 10 | 2016 | 169 | 2.280 |
Why?
|
| Drug Delivery Systems | 12 | 2020 | 273 | 1.900 |
Why?
|
| Emulsions | 8 | 2025 | 35 | 1.380 |
Why?
|
| Anti-HIV Agents | 8 | 2025 | 475 | 1.330 |
Why?
|
| Pharmaceutical Preparations | 4 | 2021 | 93 | 1.220 |
Why?
|
| Nanotechnology | 6 | 2013 | 176 | 1.070 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2018 | 101 | 0.990 |
Why?
|
| Albendazole | 1 | 2025 | 6 | 0.930 |
Why?
|
| Sweetening Agents | 1 | 2025 | 12 | 0.930 |
Why?
|
| HIV Infections | 9 | 2025 | 2535 | 0.910 |
Why?
|
| Solubility | 8 | 2025 | 134 | 0.900 |
Why?
|
| Anthelmintics | 2 | 2021 | 21 | 0.870 |
Why?
|
| Administration, Oral | 9 | 2025 | 256 | 0.870 |
Why?
|
| Benzoxazines | 3 | 2015 | 46 | 0.860 |
Why?
|
| Enema | 4 | 2018 | 10 | 0.850 |
Why?
|
| Herpesvirus 1, Human | 2 | 2023 | 64 | 0.850 |
Why?
|
| Animals | 36 | 2025 | 16695 | 0.820 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 184 | 0.800 |
Why?
|
| Gels | 5 | 2020 | 43 | 0.760 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2020 | 84 | 0.760 |
Why?
|
| Herpesvirus 2, Human | 2 | 2023 | 9 | 0.740 |
Why?
|
| Lecithins | 2 | 2011 | 3 | 0.720 |
Why?
|
| Cryptococcus neoformans | 1 | 2021 | 62 | 0.680 |
Why?
|
| HIV-1 | 5 | 2018 | 747 | 0.660 |
Why?
|
| Nanostructures | 2 | 2013 | 158 | 0.660 |
Why?
|
| Antifungal Agents | 3 | 2022 | 169 | 0.640 |
Why?
|
| Trigonella | 1 | 2019 | 2 | 0.630 |
Why?
|
| Malassezia | 1 | 2019 | 6 | 0.630 |
Why?
|
| Budesonide | 1 | 2018 | 5 | 0.590 |
Why?
|
| Biological Availability | 4 | 2025 | 115 | 0.560 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2015 | 458 | 0.560 |
Why?
|
| Nanocapsules | 2 | 2015 | 19 | 0.550 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2017 | 5 | 0.530 |
Why?
|
| Drug Stability | 5 | 2019 | 127 | 0.520 |
Why?
|
| Organophosphorus Compounds | 1 | 2017 | 37 | 0.520 |
Why?
|
| Drug Design | 2 | 2016 | 183 | 0.510 |
Why?
|
| Colitis | 1 | 2017 | 69 | 0.490 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 2015 | 11 | 0.480 |
Why?
|
| Antiviral Agents | 5 | 2023 | 189 | 0.480 |
Why?
|
| Surface-Active Agents | 3 | 2011 | 44 | 0.480 |
Why?
|
| Drug Compounding | 7 | 2020 | 90 | 0.470 |
Why?
|
| Cellulose | 1 | 2015 | 23 | 0.450 |
Why?
|
| Mice | 13 | 2025 | 6490 | 0.450 |
Why?
|
| Nanomedicine | 2 | 2013 | 52 | 0.450 |
Why?
|
| Tablets | 1 | 2014 | 11 | 0.450 |
Why?
|
| Cells | 1 | 2014 | 9 | 0.450 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 72 | 0.440 |
Why?
|
| Hela Cells | 7 | 2023 | 370 | 0.440 |
Why?
|
| Lipids | 4 | 2023 | 256 | 0.430 |
Why?
|
| Herpes Genitalis | 2 | 2023 | 6 | 0.420 |
Why?
|
| Skin | 3 | 2021 | 185 | 0.410 |
Why?
|
| Pyrrolidinones | 1 | 2012 | 10 | 0.390 |
Why?
|
| beta-Cyclodextrins | 2 | 2011 | 35 | 0.390 |
Why?
|
| Particle Size | 6 | 2019 | 267 | 0.380 |
Why?
|
| Fats | 1 | 2011 | 2 | 0.360 |
Why?
|
| Oils | 1 | 2011 | 6 | 0.360 |
Why?
|
| Humans | 27 | 2025 | 42163 | 0.350 |
Why?
|
| Colon | 3 | 2018 | 118 | 0.350 |
Why?
|
| Quercetin | 1 | 2011 | 46 | 0.340 |
Why?
|
| Phospholipids | 1 | 2011 | 69 | 0.340 |
Why?
|
| Tissue Distribution | 3 | 2025 | 230 | 0.330 |
Why?
|
| Thiazines | 2 | 2025 | 4 | 0.330 |
Why?
|
| Liposomes | 2 | 2008 | 130 | 0.320 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2016 | 122 | 0.310 |
Why?
|
| Ketorolac | 1 | 2008 | 1 | 0.300 |
Why?
|
| Poloxamer | 3 | 2022 | 13 | 0.290 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 147 | 0.290 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2022 | 232 | 0.280 |
Why?
|
| Propofol | 1 | 2008 | 8 | 0.280 |
Why?
|
| Trinitrobenzenesulfonic Acid | 2 | 2018 | 20 | 0.280 |
Why?
|
| Heptanoic Acids | 1 | 2007 | 12 | 0.280 |
Why?
|
| Rats | 6 | 2021 | 3701 | 0.280 |
Why?
|
| Antiparasitic Agents | 1 | 2007 | 10 | 0.270 |
Why?
|
| Parasitic Diseases | 1 | 2007 | 6 | 0.270 |
Why?
|
| Hypercholesterolemia | 1 | 2007 | 42 | 0.270 |
Why?
|
| Pyrroles | 1 | 2007 | 68 | 0.270 |
Why?
|
| Ceftizoxime | 1 | 2006 | 1 | 0.260 |
Why?
|
| Cisplatin | 2 | 2017 | 91 | 0.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 90 | 0.260 |
Why?
|
| Polymers | 3 | 2020 | 151 | 0.250 |
Why?
|
| Rabbits | 4 | 2021 | 292 | 0.250 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2022 | 126 | 0.250 |
Why?
|
| Cyclopropanes | 3 | 2015 | 42 | 0.240 |
Why?
|
| Alkynes | 3 | 2015 | 50 | 0.230 |
Why?
|
| Saccharin | 1 | 2025 | 9 | 0.230 |
Why?
|
| Male | 11 | 2025 | 22779 | 0.230 |
Why?
|
| Pain | 1 | 2008 | 283 | 0.220 |
Why?
|
| Temperature | 3 | 2016 | 314 | 0.220 |
Why?
|
| Antineoplastic Agents | 4 | 2017 | 979 | 0.210 |
Why?
|
| Administration, Intravesical | 2 | 2020 | 5 | 0.210 |
Why?
|
| Thiophenes | 1 | 2023 | 30 | 0.210 |
Why?
|
| Herpesviridae Infections | 1 | 2023 | 18 | 0.210 |
Why?
|
| Diffusion | 3 | 2015 | 63 | 0.200 |
Why?
|
| Water Purification | 1 | 2023 | 33 | 0.200 |
Why?
|
| Suspensions | 2 | 2018 | 48 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 415 | 0.200 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 3 | 2018 | 4 | 0.190 |
Why?
|
| Tinea | 1 | 2022 | 8 | 0.190 |
Why?
|
| Pyrimidines | 1 | 2023 | 130 | 0.190 |
Why?
|
| Malvaceae | 1 | 2022 | 4 | 0.190 |
Why?
|
| Lignans | 1 | 2022 | 22 | 0.190 |
Why?
|
| Dioctyl Sulfosuccinic Acid | 1 | 2021 | 1 | 0.180 |
Why?
|
| Candidiasis | 1 | 2022 | 86 | 0.180 |
Why?
|
| Biological Transport | 2 | 2016 | 201 | 0.180 |
Why?
|
| Coumarins | 1 | 2022 | 43 | 0.180 |
Why?
|
| Central Nervous System Diseases | 1 | 2022 | 32 | 0.180 |
Why?
|
| Rectum | 2 | 2018 | 27 | 0.180 |
Why?
|
| Reperfusion Injury | 1 | 2022 | 57 | 0.180 |
Why?
|
| Benzimidazoles | 1 | 2021 | 41 | 0.180 |
Why?
|
| Indans | 1 | 2021 | 14 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2020 | 1737 | 0.180 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2021 | 11 | 0.180 |
Why?
|
| Administration, Topical | 4 | 2020 | 37 | 0.180 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2021 | 27 | 0.170 |
Why?
|
| Adenine | 2 | 2018 | 48 | 0.170 |
Why?
|
| Ointments | 1 | 2020 | 1 | 0.170 |
Why?
|
| Acyclovir | 1 | 2020 | 7 | 0.170 |
Why?
|
| Carboxylic Acids | 1 | 2020 | 15 | 0.170 |
Why?
|
| Ophthalmic Solutions | 1 | 2020 | 18 | 0.170 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 1554 | 0.160 |
Why?
|
| Eye | 1 | 2020 | 80 | 0.160 |
Why?
|
| Strongylida Infections | 1 | 2020 | 27 | 0.160 |
Why?
|
| Butylated Hydroxytoluene | 1 | 2019 | 2 | 0.160 |
Why?
|
| Xanthophylls | 1 | 2019 | 16 | 0.160 |
Why?
|
| Skin Absorption | 3 | 2008 | 15 | 0.160 |
Why?
|
| Angiostrongylus cantonensis | 1 | 2020 | 34 | 0.160 |
Why?
|
| NF-kappa B | 1 | 2022 | 355 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2020 | 137 | 0.150 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 518 | 0.150 |
Why?
|
| Progestins | 1 | 2018 | 12 | 0.150 |
Why?
|
| Polyglycolic Acid | 3 | 2016 | 48 | 0.150 |
Why?
|
| Surface Properties | 1 | 2019 | 157 | 0.150 |
Why?
|
| Plant Leaves | 1 | 2019 | 134 | 0.150 |
Why?
|
| Neuroprotective Agents | 1 | 2022 | 267 | 0.150 |
Why?
|
| Mucus | 1 | 2018 | 15 | 0.150 |
Why?
|
| Polystyrenes | 1 | 2018 | 20 | 0.150 |
Why?
|
| HIV | 2 | 2022 | 100 | 0.150 |
Why?
|
| Lactic Acid | 3 | 2016 | 110 | 0.140 |
Why?
|
| Progesterone | 1 | 2018 | 120 | 0.140 |
Why?
|
| Infusions, Parenteral | 2 | 2008 | 13 | 0.140 |
Why?
|
| Prodrugs | 1 | 2018 | 31 | 0.140 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 74 | 0.130 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2017 | 57 | 0.130 |
Why?
|
| Premature Birth | 1 | 2018 | 94 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 1804 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2021 | 238 | 0.120 |
Why?
|
| Glioma | 1 | 2017 | 92 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2017 | 131 | 0.120 |
Why?
|
| Primary Prevention | 1 | 2016 | 63 | 0.120 |
Why?
|
| Antioxidants | 1 | 2019 | 439 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 67 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 129 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 686 | 0.110 |
Why?
|
| Calorimetry, Differential Scanning | 2 | 2011 | 36 | 0.110 |
Why?
|
| RNA, Viral | 1 | 2016 | 317 | 0.110 |
Why?
|
| Administration, Cutaneous | 2 | 2021 | 48 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2011 | 160 | 0.110 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2011 | 93 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 577 | 0.100 |
Why?
|
| AIDS Vaccines | 1 | 2013 | 25 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 602 | 0.100 |
Why?
|
| Soybean Proteins | 1 | 2012 | 38 | 0.090 |
Why?
|
| Phagocytosis | 1 | 2012 | 83 | 0.090 |
Why?
|
| Membranes, Artificial | 2 | 2023 | 33 | 0.090 |
Why?
|
| Carbamazepine | 1 | 2011 | 4 | 0.090 |
Why?
|
| Time Factors | 2 | 2016 | 1848 | 0.090 |
Why?
|
| Polysaccharides | 1 | 2012 | 70 | 0.090 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2011 | 33 | 0.090 |
Why?
|
| Polymethacrylic Acids | 1 | 2011 | 2 | 0.090 |
Why?
|
| Diglycerides | 1 | 2011 | 9 | 0.090 |
Why?
|
| Anticonvulsants | 1 | 2011 | 39 | 0.090 |
Why?
|
| Carbamates | 1 | 2011 | 13 | 0.090 |
Why?
|
| Glucose Tolerance Test | 1 | 2011 | 76 | 0.090 |
Why?
|
| Cell Line | 2 | 2013 | 1416 | 0.090 |
Why?
|
| Cryoelectron Microscopy | 1 | 2011 | 48 | 0.090 |
Why?
|
| Epilepsy | 1 | 2011 | 56 | 0.090 |
Why?
|
| Polysorbates | 1 | 2010 | 10 | 0.090 |
Why?
|
| Deoxycholic Acid | 1 | 2010 | 8 | 0.090 |
Why?
|
| Thiazoles | 1 | 2011 | 76 | 0.090 |
Why?
|
| Piperidines | 1 | 2011 | 80 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 436 | 0.090 |
Why?
|
| Micelles | 1 | 2010 | 36 | 0.080 |
Why?
|
| Transfection | 1 | 2011 | 526 | 0.080 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 184 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2010 | 95 | 0.080 |
Why?
|
| Tretinoin | 2 | 2007 | 50 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2011 | 386 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1420 | 0.070 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2007 | 385 | 0.070 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 103 | 0.070 |
Why?
|
| Cricetinae | 1 | 2008 | 241 | 0.070 |
Why?
|
| Chemistry, Physical | 1 | 2008 | 50 | 0.070 |
Why?
|
| Chemical Phenomena | 1 | 2008 | 56 | 0.070 |
Why?
|
| Administration, Intravaginal | 2 | 2018 | 8 | 0.070 |
Why?
|
| Keratolytic Agents | 1 | 2007 | 3 | 0.070 |
Why?
|
| Materials Testing | 1 | 2008 | 99 | 0.070 |
Why?
|
| Colloids | 1 | 2007 | 15 | 0.070 |
Why?
|
| Female | 6 | 2020 | 24018 | 0.070 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 101 | 0.060 |
Why?
|
| Skin Aging | 1 | 2006 | 10 | 0.060 |
Why?
|
| Retinoids | 1 | 2006 | 25 | 0.060 |
Why?
|
| Homosexuality, Male | 2 | 2022 | 483 | 0.060 |
Why?
|
| Liver | 1 | 2007 | 503 | 0.050 |
Why?
|
| Peptides | 2 | 2017 | 357 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 2598 | 0.050 |
Why?
|
| Genitalia | 1 | 2023 | 18 | 0.050 |
Why?
|
| Distillation | 1 | 2023 | 3 | 0.050 |
Why?
|
| Crystallization | 1 | 2023 | 88 | 0.050 |
Why?
|
| Minerals | 1 | 2023 | 52 | 0.050 |
Why?
|
| Macaca | 1 | 2022 | 36 | 0.050 |
Why?
|
| Biguanides | 1 | 2022 | 7 | 0.050 |
Why?
|
| Niclosamide | 1 | 2022 | 9 | 0.050 |
Why?
|
| Fluconazole | 1 | 2022 | 41 | 0.050 |
Why?
|
| Candida | 1 | 2022 | 41 | 0.050 |
Why?
|
| Cell Survival | 2 | 2017 | 934 | 0.050 |
Why?
|
| Skin Tests | 1 | 2021 | 13 | 0.040 |
Why?
|
| Rotenone | 1 | 2021 | 17 | 0.040 |
Why?
|
| Hypotonic Solutions | 1 | 2020 | 2 | 0.040 |
Why?
|
| Candida albicans | 1 | 2022 | 173 | 0.040 |
Why?
|
| Hydrogels | 1 | 2021 | 55 | 0.040 |
Why?
|
| Biofilms | 1 | 2022 | 178 | 0.040 |
Why?
|
| Locomotion | 1 | 2021 | 104 | 0.040 |
Why?
|
| Larva | 1 | 2020 | 131 | 0.040 |
Why?
|
| Swine | 1 | 2020 | 205 | 0.040 |
Why?
|
| Plant Roots | 1 | 2022 | 180 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2011 | 158 | 0.040 |
Why?
|
| Administration, Rectal | 1 | 2018 | 18 | 0.040 |
Why?
|
| Technology, Pharmaceutical | 2 | 2011 | 32 | 0.040 |
Why?
|
| Alanine | 1 | 2018 | 33 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2017 | 53 | 0.030 |
Why?
|
| Biotransformation | 1 | 2017 | 68 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2018 | 350 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2017 | 139 | 0.030 |
Why?
|
| Cadaverine | 1 | 2017 | 4 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2017 | 14 | 0.030 |
Why?
|
| Microbubbles | 1 | 2017 | 21 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 99 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 84 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 183 | 0.030 |
Why?
|
| Emulsifying Agents | 1 | 2016 | 2 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2017 | 182 | 0.030 |
Why?
|
| Vagina | 1 | 2016 | 89 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 378 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 344 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 658 | 0.030 |
Why?
|
| U937 Cells | 1 | 2013 | 30 | 0.030 |
Why?
|
| Pregnancy | 1 | 2018 | 1737 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2013 | 79 | 0.020 |
Why?
|
| Capsules | 1 | 2012 | 25 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 233 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 223 | 0.020 |
Why?
|
| Pentylenetetrazole | 1 | 2011 | 6 | 0.020 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2011 | 32 | 0.020 |
Why?
|
| Stomach Ulcer | 1 | 2011 | 8 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2011 | 66 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 276 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 300 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 1452 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 875 | 0.020 |
Why?
|
| Irritants | 1 | 2007 | 8 | 0.020 |
Why?
|
| Erythema | 1 | 2007 | 10 | 0.020 |
Why?
|
| Rheology | 1 | 2007 | 51 | 0.020 |
Why?
|
| Solvents | 1 | 2007 | 109 | 0.020 |
Why?
|
| Vitamin A Deficiency | 1 | 2006 | 13 | 0.020 |
Why?
|
| Dermatologic Agents | 1 | 2006 | 9 | 0.020 |
Why?
|
| Dermis | 1 | 2006 | 9 | 0.020 |
Why?
|
| Retinaldehyde | 1 | 2006 | 15 | 0.020 |
Why?
|
| Nicotinic Acids | 1 | 2006 | 10 | 0.020 |
Why?
|
| Epidermis | 1 | 2006 | 22 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2006 | 38 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2004 | 14 | 0.010 |
Why?
|
| Naproxen | 1 | 2004 | 10 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 4936 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2006 | 1586 | 0.010 |
Why?
|
| Adult | 1 | 2012 | 13458 | 0.010 |
Why?
|